Bard PowerPort Mass Tort Case Leads
Connect with patients who experienced device fracture, migration, embolism, or serious infection from Bard PowerPort implantable port catheter devices.
Bard PowerPort Device Litigation
The Bard PowerPort is an implantable port catheter device used to deliver medications, fluids, and blood products directly into the bloodstream, commonly used by cancer patients undergoing chemotherapy. Reports indicate these devices are prone to fracture, catheter migration, and other mechanical failures that can lead to life-threatening complications including pulmonary embolism. Lawsuits allege Bard (now part of BD) manufactured defective devices and failed to warn about the risks of device failure.
Associated Conditions
- Device fracture and catheter breakage
- Catheter migration to the heart or lungs
- Pulmonary embolism
- Infection at the port site or bloodstream
- Blood clots and deep vein thrombosis
- Cardiac arrhythmia or perforation
- Need for surgical removal or revision
Claimant Eligibility
- Had a Bard PowerPort device implanted
- Experienced device fracture, migration, or mechanical failure
- Required emergency surgery or hospitalization due to device complications
- Diagnosed with embolism, infection, or thrombosis related to the device
- Medical records documenting the device implantation and complications
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Bard PowerPort legal marketing campaigns: how we acquire cases
Bard PowerPort case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Bard PowerPort Lawsuit Updates (August 2026)
Current status of the Bard PowerPort litigation, tracked monthly so your intake team and marketing spend stay aligned with where the docket actually is.
- MDL
- MDL 3081
- Court
- D. Ariz.
Current posture: Five-case bellwether program running March through December 2026.
The next bellwether trial in the Bard PowerPort MDL was set for August 18, continuing the five-case bellwether program scheduled to run through December 2026.
A jury returned a defense verdict for Bard in the first bellwether trial of the PowerPort catheter litigation. Remaining bellwether cases continue toward trial.
The court identified the bellwether trial window running March through December 2026, during which the selected bellwether cases would be tried in sequence.
Case counts and procedural posture are compiled from JPML MDL statistics reporting and public court dockets, and are provided for law firm campaign planning. This is not legal advice and is not a prediction of any case outcome.
Running a Bard PowerPort mass tort marketing campaign
Common questions from law firms about Bard PowerPort lawsuit lead generation and campaign management.
- What does a Bard PowerPort mass tort marketing campaign include?
- A Bard PowerPort mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Bard PowerPort case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Bard PowerPort mass tort case leads?
- Bard PowerPort mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Bard PowerPort legal marketing campaigns cost?
- Bard PowerPort legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Bard PowerPort leads exclusive to my firm?
- Yes. Every Bard PowerPort lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Bard PowerPort claimants qualified before delivery?
- Each Bard PowerPort claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Bard PowerPort case acquisition program scale?
- A Bard PowerPort mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
- Do Bard PowerPort campaigns screen for SVC syndrome after a port revision?
- Yes. Superior vena cava (SVC) syndrome following catheter migration or a port revision is among the complication patterns our intake team screens for on Bard PowerPort campaigns. Screening verifies the device history, the documented complication, and the treating-provider records before a claimant is delivered to your firm — the firm makes the final eligibility determination.
Get Bard PowerPort campaign pricing on a 30-minute call
We will walk your Bard PowerPort case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.